|
July 24, 2026
TOP
NEWS
War update:
The US has launched a 13th consecutive night of strikes against Iran also president Trump mentions that he is considering a “massive
attack” on Iran, “bigger than ever before”, and that he is close to decide.
Jordan, Bahrain and Kuwait have reported missile and drone attacks from Iran
including an attack on Kuwait’s Abdali border crossing with Iraq. Brent
crossed $ 100/ barrel and all the Asian markets flaring negative with Gift
nifty indicating almost a cut of 1% on the bourses. Also, US markets were
down by almost 2% overnight.
Tariffs: The
United States on Thursday imposed a 10% tariff on imports from India lower
than 12.5% earlier. The tariff announcement comes even as India and the
United States continue negotiations on a broader trade agreement.
Fineotex Chemicals
posted a strong Q127 results. Sales were up 175% YoY
at 377cr on account of inorganic growth. EBITDA too
increased 135% YoY and reach 59 cr
and reported an EBITDA margin of 15.71% vs 18.39% 1Q26. PAT increased 93% YOY
to 48.21 cr in 1Q27. The company has an aspiration
to reach 18% EBITDA margin in medium term.
InterGlobe Aviation Q1 (Consolidated YoY): Loss stands at Rs 238 crore Vs profit
of Rs 2,176.3 crore. Revenue grows 19.9% to Rs 24,584.1 crore Vs Rs
20,496.3 cror. EBITDAR falls 33.2% to Rs 3,832.5
crore Vs Rs 5,738.6 crore. EBITDAR margin declines to 15.6% Vs 28%. ASK rises
2.9% to 43.5 billion Vs 42.3 billion. Aircraft fuel expenses zoom 85.7% to Rs
10,832.9 crore Vs Rs 5,832.6 crore. Negative
Meesho: Revenue
grew by 48% to Rs 3712 crore . 54% YoY decline in
net loss to Rs 132.8 Cr in Q1 FY27. Consolidated EBITDA loss narrowed to Rs
225 cr vs. Rs 255 cr in
4QFY26 and Rs 264 cr in 1QFY26. Meesho
aims to continue reducing logistics costs, viewing fuel price hikes and
minimum wage increases as small blips rather than long-term obstacles.
Despite these headwinds in 1Q, the company improved efficiency, reducing the
cost per delivered order by approximately one rupee
quarter-on-quarter.
Sona BLW
precision: Revenue growth of 54% yoy to Rs 1310
crore, EBITDA grew by 49% YoY to 300 cr, but EBITDA
margins fell by 0.7% YoY. A whole new Robotics & Physical AI product
segment has been added in Q1 which contributes 1% to
total revenue. Under this segment, they manufacture mission-critical hardware
such as gearboxes, sensors, etc.
Suryoday Small Finance Bank Q1 (YoY): Profit soars 113.1% to Rs 75.2 crore Vs
Rs 35.3 crore. Net interest income grows 27.8% to Rs 315.7 crore Vs Rs 247.1
crore. Provisions and contingencies fall 41% to Rs 36.7 crore Vs Rs 62.1
crore. Gross NPA increases to 6.6% Vs 6.55% (QoQ). Net NPA drops sharply to
1.27% Vs 4.21% (QoQ). Strong quarter, Positive
PREVIEW:
|
|
NII
(Rs. cr)
|
PPoP (Rs. cr)
|
PAT (Rs. Cr)
|
|
Companies
|
Q1FY27E
|
Q1FY26
|
Q4FY26
|
y-o-y
|
q-o-q
|
Q1FY27E
|
Q1FY26
|
Q4FY26
|
y-o-y
|
q-o-q
|
Q1FY27E
|
Q1FY26
|
Q4FY26
|
y-o-y
|
q-o-q
|
|
|
(%)
|
(%)
|
(%)
|
(%)
|
(%)
|
(%)
|
|
Bank of Baroda
|
12652
|
11435
|
12494
|
10.6
|
1.3
|
8301
|
8236
|
9069
|
0.8
|
-8.5
|
5043
|
4541
|
5616
|
11.1
|
-10.2
|
MACRO WRAP
- Geopolitical tensions intensified further. The
US has carried out a large-scale attack on Ahvaz in Iran's main oil
region, with more than 35 strikes so far in the past hour. With
disruptions already affecting traffic through the Strait of Hormuz,
markets are increasingly focused on the risk of a prolonged energy
supply shock. Brent crude jumped above USD100 for the first time in
almost two months. The surge in oil prices reignited inflation concerns
and pushed US Treasury yields to fresh highs for the year. The USD was
firmer and gold fell.
- The Fed funds futures raised the probability of
a 25bp hike next week to 36% and fully pricing in a 25bp hike by
September, The European Central Bank (ECB) left the Deposit Facility
Rate unchanged at 2.25% as expected. President Christine Lagarde laid
the groundwork for a possible September hike. She revealed that some
Governing Council members had questioned whether rates should have been
raised at this meeting before policymakers voted unanimously to remain
on hold, market is pricing in 90% chance of a 25bp hike in September and
a total hike of 46bp by year-end.
- The DJIA, the S&P500, and the Nasdaq
Composite Index fell 1%, 1.2%, and 2.2% respectively overnight. The Eurostoxx 50 fell 1.7%. Brent crude oil prices
jumped 7% to USD100.69. Gold fell 2% to USD4,049.
- The Dollar Index rose 0.3% to 101.44 while
EUR-USD fell around 30 pips to 1.1380. The US 2Y yield rose 5bp to 4.35%
and is already up 17bp so far this week. The US 10Y yield gained 4bp to
4.69% and is up 15bp so far this week. The US 30Y yield ticked up 1bp to
5.16%, towards the high in May of 5.18%, which was the highest level
since 2007.
- The US will impose fresh tariffs of between 10%
and 12.5% on imports from 60 economies, including China, the EU, UK, and
most ASEAN countries, citing failures to enforce bans on forced-labour
goods by Fri (24 Jul) 12:01am NY time. The timing of the new charges is
seen as a move to ensure his tariff regime remains intact even after the
stopgap 10% global duties (imposed under section 122 of the Trade Act)
expire on Fri. Those duties would be applied under Section 301 of the
1974 Trade Act, which allows the president to unilaterally impose
tariffs to combat foreign trade practices deemed to burden US commerce.
The new tariffs faced by most of the impacted economies (including
China, Japan, South Korea, Switzerland, Singapore, Thailand and Vietnam)
are 12.5%, while a smaller group (including Canada, EU, Taiwan, UK,
Indonesia and Malaysia) faces 10%. India secured a 10% tariff instead of
the originally threatened 12.5% rate.
- Japan’s annual inflation rose to 1.7% in June
2026 from 1.5% in May, the highest since December, mainly as reduced
energy subsidies slowed the decline in electricity and gas prices.
Inflation picked up in several categories, while food inflation eased to
3.2% amid falling rice prices. Core inflation climbed to 1.6%, its highest since March but below the Bank of Japan’s
2% target for the fifth month in a row.
- The ECB left rates unchanged in July after a 25
bp hike in June, shifting to a wait-and-see stance amid softer
inflation, wage growth, activity, and expectations. It said energy
prices remain volatile but broadly in line with forecasts, warning that
prolonged high energy costs could still fuel broader inflation through
indirect and second-round effects.
- The US trade deficit widened to $77.6 billion
in May 2026 from $54.6 billion in April, the largest since March 2025,
as imports rose and exports declined, pointing to a bigger drag from net
exports on Q2 GDP amid ongoing US trade-policy uncertainty.
- Data watch: the Jul PMI, US data docket will
include Jun new home sales (Bloomberg est. 4.7% m/m, 606,000 units from
-7.3%, 580,000 units in May).
INVESTMENT CALL
First Cut: Infosys: Weak guidance and even weaker organic growth
- Infosys posted revenue of $ 5,082
million, up 0.8% q-o-q (up 2.9% y-o-y), in line with our estimates. In
CC, the company posted a growth of 1.0% q-o-q (up 2.4% y-o-y), including
1.1% sequential contribution from acquisition resulting in flat to
negative organic growth for a seasonal strong quarter, mainly due to a
50bps impact on account of program termination by a EURS client along
with weaker volumes compared to historical levels.
- Infosys lowered its FY27 revenue
growth guidance to 1.5%-3.0% CC primarily due to a combination of a
one-time program termination by a client in the EURS segment,
softer-than-expected volumes, weaker pricing realization amid increased
competitive intensity, and continued macroeconomic uncertainty that has
delayed discretionary spending and elongated client decision-making
cycles.
- Management also highlighted additional
headwinds from reduced spending by a large European manufacturing client
(impacting 100bps growth), ongoing offshoring-led revenue dilution
(75-100bps impact), and its decision not to pursue certain deals that
did not meet return thresholds.
- On the inorganic front, acquisition
particularly Optimum Healthcare IT and Stratus, are expected to
contribute around 1.7% to FY27 revenue growth. The acquisitions are
strengthening Infosys' presence in healthcare, life sciences, insurance,
and related digital transformation areas, with management specifically
expecting the Life Sciences and Healthcare segments to benefit from
these acquisitions and partially offset the softness in the broader
demand environment.
- Q1 Numbers: Revenue came in at Rs.
48,211 crores, up 3.9% q-o-q (14.0% y-o-y), largely in-line with our
estimates. Adj. EBIT stood at Rs. 10,163 Cr, up 4.3% q-o-q (15.4%
y-o-y). Adj. EBIT Margin came in at 21.1%. Adjusted PAT came in at Rs.
7,769 crores, down 8.6% q-o-q and 12.3% y-o-y.
|
Particulars
|
Q1FY27
|
Q1FY26
|
Q4FY26
|
YoY
(%)
|
QoQ
(%)
|
|
Revenues In USD (Mn)
|
5,082
|
4,941
|
5,040
|
2.9
|
0.8
|
|
QoQ CC growth (%)
|
1.0
|
2.6
|
-1.3
|
-160
|
230
|
|
YoY CC growth (%)
|
2.4
|
3.8
|
4.1
|
-140
|
-170
|
|
Revenues In INR (Cr)
|
48,211
|
42,279
|
46,402
|
14.0
|
3.9
|
|
EBITDA
|
11,409
|
9,943
|
11,167
|
14.7
|
2.2
|
|
EBIT
|
10,163
|
8,803
|
9,743
|
15.4
|
4.3
|
|
PAT
|
7,775
|
6,924
|
8,509
|
12.3
|
-8.6
|
|
Adj. PAT
|
7,769.0
|
6,921.0
|
8,501
|
12.3
|
-8.6
|
|
|
|
|
|
|
|
|
Margin (%)
|
|
|
|
|
|
|
GPM
|
34.1
|
33.6
|
34.0
|
49
|
9
|
|
EBITDA
|
23.7
|
23.5
|
24.1
|
15
|
-40
|
|
EBIT
|
21.1
|
20.8
|
21.0
|
26
|
8
|
|
NPM
|
16.1
|
16.4
|
18.3
|
-26
|
-221
|
|
Tax Rate
|
29.5
|
28.9
|
21.2
|
59
|
831
|
|
Particulars
|
Q1FY27A
|
Q1FY27E
|
Variance
|
|
Revenues In USD (Mn)
|
5,082
|
5,106
|
-0.5%
|
|
Revenues In INR (Cr)
|
48,211
|
48,250
|
-0.1%
|
|
EBIT
|
10,163
|
10,427
|
-2.5%
|
|
Adj. PAT
|
7,769
|
8,078
|
-3.8%
|
|
GPM
|
34.1
|
34.4
|
-34.4
|
|
EBITDA
|
23.7
|
24.6
|
-94.6
|
|
EBIT
|
21.1
|
21.6
|
-53.1
|
|
NPM
|
16.1
|
16.7
|
-62.7
|
|
Tax Rate
|
29.5
|
29.0
|
49.8
|
Stock Update: SRF All-round beat in Q1; H2 outlook better
Reco:
BUY
CMP: Rs. 2,626
Target:
3,100
- Q1FY27 numbers beat estimates, led by robust
growth in PFB and better-than-seasonal performance in the chemical
segment.
- 2Q27 to be a lower q-o-q, owing to seasonality
on account of slightly softer Chemical sector but should grow y-o-y. 2H
has always been stronger and H2FY27 should be better compared with H1.
- PFB segment’s margins are expected to be
supported by some stabilisation in realizations on the subsidiary side,
while moving up the VAP mix should further aid margin expansion.
- Despite a slightly soft Q227, we expect 2H27 to
be strong driven by fluorochemicals, richer product mix in PFB. We
retain a BUY on SRF with a SOTP price of Rs 3,100.
|
|
|
|
Rs Cr
|
|
Particular
|
FY25A
|
FY26A
|
FY27E
|
FY28E
|
|
Revenue
|
14,693
|
15,787
|
18,099
|
21,680
|
|
EBITDA Margin%
|
19.3%
|
23.4%
|
25.2%
|
23.6%
|
|
Adjusted PAT
|
1,251
|
2,019
|
2,580
|
2,974
|
|
YoY growth %
|
-90.6%
|
61.4%
|
27.8%
|
15.3%
|
|
Adjusted EPS
|
42.2
|
68.1
|
87.1
|
100.4
|
|
P/E(x)
|
64.5
|
40.0
|
31.3
|
27.1
|
|
EV/EBITDA(x)
|
30.0
|
23.0
|
18.6
|
16.7
|
|
RoNW(%)
|
10.4%
|
15.1%
|
17.0%
|
16.8%
|
|
RoCE%
|
12.3%
|
16.1%
|
16.4%
|
16.8%
|
Viewpoint- Sunteck Realty – On a robust growth path
View:
Positive
CMP: Rs. 304
Target: 444
- Pre-sales
rose 19.8% y-o-y to Rs. 787 crore in Q1FY27,
led by strong traction in the premium and uber-luxury segments, while
collections grew 16.5% y-o-y to Rs. 409 crore.
- Management
reiterated its FY27 pre-sales growth guidance of 25–30% y-o-y, backed by
~Rs. 7,000–7,100 crore of planned domestic launches (excluding the Rs.
9,000 crore Dubai project).
- The fully-approved, launch-ready Downtown Dubai project
remains a meaningful optional upside trigger, with the launch awaiting a
more conducive external environment.
- We
remain positive on Sunteck Realty, with a
revised PT of Rs. 444, supported by a strong launch pipeline, robust
cash flows and attractive valuation.
|
Particulars
|
FY25
|
FY26
|
FY27E
|
FY28E
|
|
Revenue
|
853.1
|
1123.8
|
1380.8
|
1593.8
|
|
OPM (%)
|
21.8
|
27.1
|
28.3
|
29.4
|
|
Adjusted PAT
|
150.3
|
202.1
|
246.8
|
290.4
|
|
YoY growth (%)
|
111.9
|
34.4
|
22.2
|
17.6
|
|
Adjusted EPS (Rs.)
|
10.3
|
13.8
|
16.9
|
19.8
|
|
P/E (x)
|
29.6
|
22.1
|
18.1
|
15.3
|
|
P/B (x)
|
1.4
|
1.2
|
1.2
|
1.1
|
|
EV/EBITDA (x)
|
25.0
|
19.7
|
16.9
|
12.6
|
|
RoNW (%)
|
4.7
|
5.9
|
6.8
|
7.6
|
|
RoCE (%)
|
6.3
|
7.6
|
8.7
|
11.0
|
First Cut:
Mahindra Lifespace Developers Ltd Q1FY27
Consolidated Results – Strong bounce-back
performance
- Pre-sales increased by 106% YoY to Rs. 925 crore, while collections rose by 2% YoY to Rs. 527 crore. Sustenance sales contributed around 42% of
total sales, led by projects such as Blossom, Vista, Marina 64, and IvyLush.
- MLDL reported consolidated net revenues of
Rs. 962 crore in Q1FY27, marking a sharp bounce
back from Rs. 32 crore in Q1FY26. EBITDA turned
positive at Rs. 94.5 crore, compared with a loss of Rs. 55 crore in the corresponding quarter last year,
supported by new launches and strong execution.
- Net profit stood at Rs. 86 crore, up 66.9% YoY, driven by higher revenue
recognition and improved operating performance.
- The company continues to maintain a robust
balance sheet with a net debt-to-equity ratio of -0.20x. Total GDV
stands at approximately Rs. 50 K crore
|
Particulars
|
Q1FY27
|
Q1FY26
|
YoY
(%)
|
Q4FY26
|
QoQ
(%)
|
|
Net Sales
|
962.1
|
32.0
|
2909.5
|
669.6
|
43.7
|
|
Operating Profit
|
94.5
|
-55.0
|
NA
|
-43.9
|
NA
|
|
Adjusted PAT
|
85.6
|
51.3
|
66.9
|
90.1
|
-5.1
|
|
EPS (Rs.)
|
4.0
|
3.3
|
21.0
|
4.2
|
-5.1
|
|
|
|
|
|
|
|
|
OPM(%)
|
9.8
|
-172.1
|
NA
|
-6.6
|
1637
bps
|
|
NPM (%)
|
8.9
|
160.3
|
NA
|
13.5
|
-457
bps
|
|
Tax rate (%)
|
22.9
|
-23.2
|
NA
|
-7.0
|
2991
bps
|
OTHERS
Motilal Oswal Financial Services Q1 (Consolidated YoY): Profit rises
9.6% to Rs 1,273.1 crore Vs Rs 1,162.1 crore. Revenue surges 25.1% to Rs
3,425.8 crore Vs Rs 2,737.8 crore.
Shadowfax
Technologies: Eight Roads, Flipkart, and Korea's IMM India Fund are likely to
sell shares worth more than Rs 1,000 crore in Shadowfax through block deals,
with a floor price of Rs 197 per share, according to broker details reviewed
by Moneycontrol.
|